Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2842

Sort by

Sort Order Select

Journal Articles

Early time to relapse as a survival prognosticator in mature T-cell/NK-cell lymphomas: results from the PETAL Consortium

Blood blood.2025030149.

https://doi.org/10.1182/blood.2025030149

Published: 2025

Includes: Supplemental data

Journal Articles

Evolution of Multiple Myeloma from a Genomic Perspective

Francesco Maura, Mehmet K. Samur, Nikhil C. Munshi

Blood blood.2024026313.

https://doi.org/10.1182/blood.2024026313

Published: 2025

Journal Articles

Donor-derived CD7 CAR T cells for pediatric and adult relapsed/refractory T-ALL/LBL: a phase 2 trial

Blood (2025) 146 (23): 2745–2757.

https://doi.org/10.1182/blood.2025029299

Published: 2025

Includes: Supplemental data

Journal Articles

The origin, diagnosis, and prognosis of oligomannose-type diffuse large B-cell lymphoma

Dylan J. Tatterton, Maddy L. Newby, Joel D. Allen, Benjamin Sale, Giorgia Chiodin, Patrick J. Duriez, John Butler, Katy J. McCann, David W. Scott, Ryan D. Morin, Kostiantyn Dreval, Andrew J. Davies, Dean J. Bryant, Max Crispin, Francesco Forconi

Blood (2025) 146 (23): 2808–2820.

https://doi.org/10.1182/blood.2025029163

Published: 2025

Includes: Supplemental data

Journal Articles

Nanoromidepsin, a polymer nanoparticle of the HDAC inhibitor, improves safety and efficacy in models of T-cell lymphoma

Ipsita Pal, Anuradha Illendula, Andrea Joyner, John Sanil Manavalan, Tess M. Deddens, Ariana Sabzevari, Deepthi P. Damera, Samir Zuberi, Enrica Marchi, Todd E. Fox, Marya E. Dunlap-Brown, Kallesh D. Jayappa, Jihane Khalife, Jeffrey W. Craig, Thomas P. Loughran, Jr., David J. Feith, Owen A. O’Connor

Blood (2025) 146 (23): 2794–2807.

https://doi.org/10.1182/blood.2024027997

Published: 2025

Includes: Supplemental data

Journal Articles

Leukemia escapes immunity by imposing a type 1 regulatory program on neoantigen-specific CD4 + T cells

Hrishi Venkatesh, Enoc Granados Centeno, Qianyun Luo, Miriam Arroyo, Lynn Heltemes-Harris, Todd P. Knutson, Yinjie Qiu, Allison Haaning, Beau R. Webber, Veronika Bachanova, Michael A. Farrar, Sean I. Tracy

Blood (2025) 146 (23): 2779–2793.

https://doi.org/10.1182/blood.2024028194

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial

Blood (2025) 146 (23): 2758–2764.

https://doi.org/10.1182/blood.2025028823

Published: 2025

Includes: Supplemental data

Journal Articles

Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling

Sina A. Beer, David A. Cairns, Charlotte Pawlyn, Amy Holroyd, Elsa Ferris, Gordon Cook, Mark Drayson, Kevin Boyd, Paula Proszek, Faith E. Davies, Ruth de Tute, Matthew Jenner, Gareth J. Morgan, Roger Owen, Michael Hubank, Richard Houlston, Graham Jackson, Martin F. Kaiser

Blood (2025) 146 (22): 2670–2680.

https://doi.org/10.1182/blood.2025029987

Published: 2025

Includes: Supplemental data

Journal Articles

Fixed-duration epcoritamab plus R 2 drives favorable outcomes in relapsed or refractory follicular lymphoma

Blood (2025) 146 (22): 2629–2640.

https://doi.org/10.1182/blood.2025029909

Published: 2025

Includes: Supplemental data

Journal Articles

Prior transplantation and idecabtagene vicleucel in multiple myeloma: a secondary analysis of CIBMTR data

Rahul Banerjee, Christy Khouderchah, Othman Salim Akhtar, Emily C. Liang, Jordan Gauthier, Madhav V. Dhodapkar, Andrew J. Portuguese

Blood blood.2025031426.

https://doi.org/10.1182/blood.2025031426

Published: 2025

Includes: Supplemental data

Journal Articles

Gene expression profiling reveals two overarching types of ALCL with distinct targetable biology: an LLMPP study

Andrew L. Feldman, Surendra Dasari, Lisa M. Rimsza, David W. Scott, Naoki Oishi, Guangzhen Hu, Pedro Farinha, Catalina Amador, Elías Campo, Wing C. Chan, James R. Cook, Jan Delabie, Kai Fu, Timothy C Greiner, Laura K Hilton, Giorgio GA Inghirami, Javeed Iqbal, Elaine S Jaffe, Ryan Morin, Sarah L. Ondrejka, German Ott, Stefania Pittaluga, Philipp W Raess, Andreas Rosenwald, Kerry J. Savage, Graham W. Slack, Susan L. Slager, Joo Y Song, George Wright, Hao-Wei Wang, Yu Zeng, Tadashi Yoshino, Xiaojun Wu, Ryan A Wilcox, xueju wang, Min Shi, Akira Satou, Anamarija M Perry, Roberto Nicolas Miranda, L.Jeffrey Jeffrey Medeiros, Matthew J Maurer, Eric Mou, Young Hyeh Ko, Kennosuke Karube, Brad S Kahl, Liuyan Jiang, David L Jaye, Alejandro Gru, Laurence L de Leval, Weina Chen, Jennifer R. Chapman, James R Cerhan, Carlos Barrionuevo, Stephen M. Ansell, Ahmed Aljudi

Blood blood.2024027700.

https://doi.org/10.1182/blood.2024027700

Published: 2025

Includes: Supplemental data

Journal Articles

TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma

Blood (2025) 146 (21): 2544–2560.

https://doi.org/10.1182/blood.2024026919

Published: 2025

Includes: Supplemental data

Journal Articles

A T-cell–based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy

Wassilis S. C. Bruins, Febe Smits, Carolien Duetz, Kaz Groen, Charlotte L. B. M. Korst, A. Vera de Jonge, Christie P. M. Verkleij, Rosa Rentenaar, Meliha Cosovic, Merve Eken, Inoka Twickler, Paola M. Homan-Weert, Pieter Sonneveld, Philippe Moreau, Jürgen Claesen, Niels W. C. J. van de Donk, Sonja Zweegman, Tuna Mutis

Blood (2025) 146 (21): 2517–2530.

https://doi.org/10.1182/blood.2025028587

Published: 2025

Includes: Supplemental data

Journal Articles

A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma

Peng-Peng Xu, Yue Zhu, Zi-Yang Shi, Li Wang, Shu Cheng, Ying Qian, Yan Zhao, Yang He, Hong-Mei Yi, Bin-shen Ou-yang, Xu-Feng Jiang, Biao Li, Qi Song, Rong-Ji Mu, Wei-Li Zhao

Blood (2025) 146 (21): 2561–2573.

https://doi.org/10.1182/blood.2025028649

Published: 2025

Includes: Supplemental data

Journal Articles

Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702)

Terri L. Parker, Adam Rosenthal, Vaishali Sanchorawala, Heather J. Landau, Erica L. Campagnaro, Prashant Kapoor, Natalia Neparidze, Saulius Girnius, Patrick Hagen, Emma C. Scott, Antje Hoering, Brian G. M. Durie, Robert Z. Orlowski

Blood (2025) 146 (21): 2507–2516.

https://doi.org/10.1182/blood.2024027962

Published: 2025

Journal Articles

Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma

Joshua Rivera, Qi Yan, Saeed Daneshmandi, Romain Lannes, Eriko Katsuta, JeeEun Choi, Prashant Singh, Ahmed Belal, Ronald Alberico, Ian Lund, Megan Schaefer, Hamza Hassan, Sarah Parker, Kenneth C. Anderson, Nikhil C. Munshi, Mehmet Samur, Philip L. McCarthy, Jens Hillengass, Hemn Mohammadpour

Blood (2025) 146 (20): 2392–2405.

https://doi.org/10.1182/blood.2025028963

Published: 2025

Includes: Supplemental data

Journal Articles

Risk factors and outcomes of asparaginase-associated pancreatitis in pediatric patients with ALL

Blood (2025) 146 (20): 2417–2427.

https://doi.org/10.1182/blood.2025029785

Published: 2025

Includes: Supplemental data

Journal Articles

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL

Blood (2025) 146 (20): 2406–2416.

https://doi.org/10.1182/blood.2025028899

Published: 2025

Includes: Supplemental data

Journal Articles

Mantle cell lymphoma with KMT2A rearrangement

Shimin Hu, Guilin Tang

Blood (2025) 146 (20): 2491.

https://doi.org/10.1182/blood.2025030135

Published: 2025

Journal Articles

Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia

Roberta S. Azevedo, Elias Jabbour, Hagop M Kantarjian, Sravanthi Lavu, Sanam Loghavi, Nitin Jain, Koji Sasaki, Rebecca Garris, Koichi Takahashi, Farhad Ravandi, Nicholas J. Short

Blood blood.2025030498.

https://doi.org/10.1182/blood.2025030498

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Early time to relapse as a survival prognosticator in mature T-cell/NK-cell lymphomas: results from the PETAL Consortium

Evolution of Multiple Myeloma from a Genomic Perspective

Donor-derived CD7 CAR T cells for pediatric and adult relapsed/refractory T-ALL/LBL: a phase 2 trial

The origin, diagnosis, and prognosis of oligomannose-type diffuse large B-cell lymphoma

Nanoromidepsin, a polymer nanoparticle of the HDAC inhibitor, improves safety and efficacy in models of T-cell lymphoma

Leukemia escapes immunity by imposing a type 1 regulatory program on neoantigen-specific CD4 + T cells

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial

Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling

Fixed-duration epcoritamab plus R 2 drives favorable outcomes in relapsed or refractory follicular lymphoma

Prior transplantation and idecabtagene vicleucel in multiple myeloma: a secondary analysis of CIBMTR data

Gene expression profiling reveals two overarching types of ALCL with distinct targetable biology: an LLMPP study

TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma

A T-cell–based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy

A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma

Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702)

Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma

Risk factors and outcomes of asparaginase-associated pancreatitis in pediatric patients with ALL

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL

Mantle cell lymphoma with KMT2A rearrangement

Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only